Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease

References

• Greenberg CS, Lai TS, Ariens RAS, Weisel JW, Grant PJ. Biology and disorders of fibrinogen and Factor XIII. In: Blood-principles and practice of hematology. Handin RI, Lux SE, Stossel TO (Eds.). Lippincott Williams & Wilkins, 1225–1248 (2001).
   Google Scholar
• Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb. Haemost. 85, 470–474 (2001).
   PubMed Web of Science ®Google Scholar
• Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (Factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb. Haemost. 86, 1221–1228 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper AV, Standeven KF, Ariens RA. Fibrinogen γ-chain splice variant-γ alters fibrin formation and structure. Blood 102, 535–540 (2003).
   PubMed Web of Science ®Google Scholar
• Lovely RS, Falls LA, Al Mondhiry HA et al. Association of γA/γ´ fibrinogen levels and coronary artery disease. Thromb. Haemost. 88, 26–31 (2002).
   PubMed Web of Science ®Google Scholar
• Norris LA. Blood coagulation. Best Pract. Res. Clin. Obstet. Gynaecol. 17, 369–383 (2003).
   PubMed Web of Science ®Google Scholar
• Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann. NY Acad. Sci. 936, 594–610 (2001).
   PubMed Web of Science ®Google Scholar
• Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb. Haemost. 89, 409–419 (2003).
   PubMed Web of Science ®Google Scholar
• Fatah K, Silveira A, Tornvall P et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb. Haemost. 76, 535–540 (1996).
   PubMed Web of Science ®Google Scholar
• Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb. Haemost. 68, 130–135 (1992).
   PubMed Web of Science ®Google Scholar
• Jorneskog G, Egberg N, Fagrell B et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39, 1519–1523 (1996).
   PubMed Web of Science ®Google Scholar
• Shats EA, Nair CH, Dhall DP. Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis. Atherosclerosis 129, 9–15 (1997).
   PubMed Web of Science ®Google Scholar
• Collet JP, Park D, Lesty C et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler. Thromb. Vasc. Biol. 20, 1354–1361 (2000).
   PubMed Web of Science ®Google Scholar
• Blomback B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb. Res. 75, 327–328 (1994).
   PubMed Web of Science ®Google Scholar
• Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb. Haemost. 89, 601–609 (2003).
   PubMed Web of Science ®Google Scholar
• Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2, 533–537 (1986).
   PubMed Web of Science ®Google Scholar
• Collet JP, Soria J, Mirshahi M et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 82, 2462–2469 (1993).
   PubMed Web of Science ®Google Scholar
• Ariens RA, de Lange M, Snieder H et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359, 667–671 (2002).
   PubMed Web of Science ®Google Scholar
• de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 357, 101–105 (2001).
   PubMed Web of Science ®Google Scholar
• Peetz D, Victor A, Adams P et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb. Haemost. 92, 344–351 (2004).
   PubMed Web of Science ®Google Scholar
• Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106, 1938–1942 (2002).
   PubMed Web of Science ®Google Scholar
• Yu S, Sher B, Kudryk B, Redman CM. Fibrinogen precursors. Order of assembly of fibrinogen chains. J. Biol.Chem. 259, 10574–10581 (1984).
   Google Scholar
• Grant PJ, Humphries SE. Genetic determinants of arterial thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12, 505–532 (1999).
   PubMed Web of Science ®Google Scholar
• Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann. NY Acad. Sci. 936, 549–559 (2001).
   PubMed Web of Science ®Google Scholar
• Iacoviello L, Vischetti M, Zito F, Benedetta DM. Genes encoding fibrinogen and cardiovascular risk. Hypertension 38, 1199–1203 (2001).
   PubMed Web of Science ®Google Scholar
• Grant PJ. The genetics of atherothrombotic disorders: a clinician’s view. J.Thromb. Haemost. 1, 1381–1390 (2003).
   PubMed Web of Science ®Google Scholar
• Standeven KF, Grant PJ, Carter AM et al. Functional analysis of the fibrinogen A αThR312Ala polymorphism: effects on fibrin structure and function. Circulation 107, 2326–2330 (2003).
   PubMed Web of Science ®Google Scholar
• Carter AM, Catto AJ, Grant PJ. Association of the α-fibrinogen ThR312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 99, 2423–2426 (1999).
   PubMed Web of Science ®Google Scholar
• Carter AM, Catto AJ, Kohler HP et al. α-fibrinogen ThR312Ala polymorphism and venous thromboembolism. Blood 96, 1177–1179 (2000).
   PubMed Web of Science ®Google Scholar
• Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene–environment interactions may modulate vascular risk. Lancet 361, 1424–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Maghzal GJ, Brennan SO, George PM. Fibrinogen Bβ polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thromb. Haemost. 90, 1021–1028 (2003).
   PubMed Web of Science ®Google Scholar
• Behague I, Poirier O, Nicaud V et al. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l’Infarctus du Myocarde. Circulation 93, 440–449 (1996).
   PubMed Web of Science ®Google Scholar
• Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 17, 589–594 (1997).
   PubMed Web of Science ®Google Scholar
• Attie-Castro FA, Zago MA, Lavinha J et al. Ethnic heterogeneity of the Factor XIII Val34Leu polymorphism. Thromb. Haemost. 84, 601–603 (2000).
   PubMed Web of Science ®Google Scholar
• Kohler HP, Stickland MH, Ossei-Gerning N et al. Association of a common polymorphism in the Factor XIII gene with myocardial infarction. Thromb. Haemost. 79, 8–13 (1998).
   PubMed Web of Science ®Google Scholar
• Ariens RA, Philippou H, Nagaswami C et al. The Factor XIII V34L polymorphism accelerates thrombin activation of Factor XIII and affects cross-linked fibrin structure. Blood 96, 988–995 (2000).
   PubMed Web of Science ®Google Scholar
• Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of Factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100, 743–754 (2002).
   PubMed Web of Science ®Google Scholar
• Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys.Chem. 112, 223–228 (2004).
   PubMed Web of Science ®Google Scholar
• Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb. Haemost. 86, 366–373 (2001).
   PubMed Web of Science ®Google Scholar
• Humphries SE, Lane A, Dawson S, Green FR. The study of gene–environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for Factor VII and plasminogen activator inhibitor-1. Arch. Pathol. Lab. Med. 116, 1322–1329 (1992).
   PubMed Web of Science ®Google Scholar
• Zhan M, Zhou Y, Han ZC. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int. J. Hematol. 79, 400–404 (2004).
   PubMed Web of Science ®Google Scholar
• Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb. Haemost. 91, 861–872 (2004).
   PubMed Web of Science ®Google Scholar
• Iacoviello L, Burzotta F, Di Castelnuovo A et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb. Haemost. 80, 1029–1030 (1998).
   PubMed Web of Science ®Google Scholar
• Hammar N, Kaprio J, Hagstrom U et al. Migration and mortality: a 20 year follow-up of Finnish twin pairs with migrant co-twins in Sweden. J. Epidemiol. Community Health 56, 362–366 (2002).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241, 2035–2038 (1979).
   PubMed Web of Science ®Google Scholar
• Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21, 1167–1172 (1998).
   PubMed Web of Science ®Google Scholar
• Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 29, 470–479 (2004).
   PubMed Web of Science ®Google Scholar
• Fanghanel G, Silva U, Sanchez-Reyes L et al. Effects of metformin on fibrinogen levels in obese patients with Type 2 diabetes. Rev. Invest. Clin. 50, 389–394 (1998).
   PubMedGoogle Scholar
• Cefalu WT, Schneider DJ, Carlson HE et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled Type 2 diabetic subjects. Diabetes Care 25, 2123–2128 (2002).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Panahloo A, Stehouwer C et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 43, 1099–1106 (2000).
   PubMed Web of Science ®Google Scholar
• Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD. Glycated fibrinogen: a new index of short-term diabetic control. Ann. Clin. Biochem. 26 (Pt. 1), 58–62 (1989).
   Google Scholar
• Dunn E, Ariens RAS, Grant PJ. The influence of Type 2 diabetes on clot structure and function. Diabetologia 48(6), 1198–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Jorneskog G, Hansson LO, Wallen NH, Yngen M, Blomback M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J.Thromb. Haemost. 1, 1195–1201 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am. J. Cardiol. 92, i10–i18 (2003).
   Google Scholar
• Speidl WS, Zeiner A, Nikfardjam M et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll. Cardiol. 45, 30–34 (2005).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398–404 (2003).
   PubMed Web of Science ®Google Scholar
• Shats-Tseytlina EA, Nair CH, Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul. Fibrinolysis 5, 529–535 (1994).
   PubMed Web of Science ®Google Scholar
• Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with Type 2 diabetes at five years of follow-up. Diabetologia 48, 386–393 (2005).
   PubMed Web of Science ®Google Scholar
• Esmon CT. Inflammation and thrombosis. J.Thromb. Haemost. 1, 1343–1348 (2003).
   Web of Science ®Google Scholar
• Veldman FJ, Nair CH, Vorster HH et al. Dietary pectin influences fibrin network structure in hypercholesterolaemic subjects. Thromb.Res. 86, 183–196 (1997).
   PubMed Web of Science ®Google Scholar
• de Lange DW, van de WA. Drink to prevent: review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Semin. Vasc. Med. 4, 173–186 (2004).
   PubMedGoogle Scholar
• Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J. Am. Coll. Cardiol. 44, 152–158 (2004).
   PubMed Web of Science ®Google Scholar
• Oosthuizen W, Vorster HH, Jerling JC et al. Both fish oil and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb. Haemost. 72, 557–562 (1994).
   PubMed Web of Science ®Google Scholar
• de Gaetano G, Di Castelnuovo A, Donati MB, Iacoviello L. The Mediterranean lecture: wine and thrombosis – from epidemiology to physiology and back. Pathophysiol. Haemost. Thromb. 33, 466–471 (2003).
   PubMedGoogle Scholar
• Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477–1482 (1998).
   PubMed Web of Science ®Google Scholar
• Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and Factor VII activity. Br. Heart J. 67, 351–354 (1992).
   PubMedGoogle Scholar
• Gibbs CR, Blann AD, Edmunds E, Watson RD, Lip GY. Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm. Clin. Cardiol. 24, 724–729 (2001).
   PubMed Web of Science ®Google Scholar
• Iso H, Shimamoto T, Sato S et al. Passive smoking and plasma fibrinogen concentrations. Am. J. Epidemiol. 144, 1151–1154 (1996).
   PubMed Web of Science ®Google Scholar
• de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann. NY Acad. Sci. 936, 509–521 (2001).
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Valadier J, Alessi MC et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57, 67–72 (1987).
   PubMed Web of Science ®Google Scholar
• Tekin A, Tekin G, Guzelsoy D et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am. J. Cardiol. 94, 206–209 (2004).
   PubMed Web of Science ®Google Scholar
• Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler. Thromb. 12, 19–27 (1992).
   PubMedGoogle Scholar
• Latron Y, Chautan M, Anfosso F et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Thromb. 11, 1821–1829 (1991).
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J. Pharmacol. Exp. Ther. 250, 154–161 (1989).
   PubMed Web of Science ®Google Scholar
• Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann. NY Acad. Sci. 936, 580–593 (2001).
   PubMed Web of Science ®Google Scholar
• He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann. NY Acad. Sci. 936, 531–535 (2001).
   PubMed Web of Science ®Google Scholar
• Mazoyer E, Ripoll L, Boisseau MR, Droue L. How does ticlopidine treatment lower plasma fibrinogen? Thromb. Res. 75, 361–370 (1994).
   PubMed Web of Science ®Google Scholar
• Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J. Thromb. Haemost. 2, 1934–1940 (2004).
   PubMed Web of Science ®Google Scholar
• Undas A, Sydor WJ, Brummel K et al. Aspirin alters the cardioprotective effects of the Factor XIII Val34Leu polymorphism. Circulation 107, 17–20 (2003).
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Lazzari P et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. Pharmacol. 32, 616–620 (1998).
   PubMed Web of Science ®Google Scholar
• Makris TK, Stavroulakis GA, Krespi PG et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am. J. Hypertens. 13, 783–788 (2000).
   PubMed Web of Science ®Google Scholar
• Makris TK, Stavroulakis G, Papadopoulos DP et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp. Clin. Res. 30, 125–132 (2004).
   PubMedGoogle Scholar
• Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 110, 886–892 (2004).
   PubMed Web of Science ®Google Scholar
• Balk EM, Lau J, Goudas LC et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 139, 670–682 (2003).
   PubMed Web of Science ®Google Scholar
• Okopien B, Krysiak R, Madej A et al. Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia. Pol. J. Pharmacol. 56, 781–787 (2004).
   PubMedGoogle Scholar
• Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb. Res. 105, 285–290 (2002).
   PubMed Web of Science ®Google Scholar
• Dangas G, Badimon JJ, Smith DA et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33, 1294–1304 (1999).
   PubMed Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18, 269–276 (2002).
   PubMed Web of Science ®Google Scholar
• Kockx M, Gervois PP, Poulain P et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor. Blood 93, 2991–2998 (1999).
   PubMed Web of Science ®Google Scholar
• Okopien B, Cwalina L, Lebek M et al. Effects of fibrates on plasma prothrombotic activity in patients with Type IIb dyslipidemia. Int. J. Clin. Pharmacol. Ther. 39, 551–557 (2001).
   PubMed Web of Science ®Google Scholar
• UK Prospective DiabetesStudy (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 29, 6S44–6S52 (2003).
   PubMed Web of Science ®Google Scholar
• Charles MA, Morange P, Eschwege E et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 21, 1967–1972 (1998).
   PubMed Web of Science ®Google Scholar
• Standeven KF, Ariens RA, Whitaker P et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51, 189–197 (2002).
   PubMed Web of Science ®Google Scholar
• Dhall DP, Nair CH. Effects of gliclazide on fibrin network. J. Diabetes Complications 8, 231–234 (1994).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Heckbert SR, Atkins D et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch. Intern. Med. 153, 1421–1427 (1993).
   PubMedGoogle Scholar
• Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am. J. Cardiol. 90, F7–F10 (2002).
   Google Scholar
• Giri S, Thompson PD, Taxel P et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 137, 359–366 (1998).
   PubMed Web of Science ®Google Scholar
• Khan NS, Malhotra S. Effect of hormone replacement therapy on cardiovascular disease: current opinion. Expert. Opin. Pharmacother. 4, 667–674 (2003).
   PubMed Web of Science ®Google Scholar
• Gurewich V. Ximelagatran–promises and concerns. JAMA 293, 736–739 (2005).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789–797 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best. Pract. Res. Clin. Haematol. 17, 89–104 (2004).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Murphy SA, McCabe CH et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur. Heart J. (2005).
   Google Scholar
• Bianucci AM, Massarelli I, Chiellini F, Eidelman C, Chiellini E. Design of highly specific ligands of fibrin for therapeutic applications. J. Biomater. Sci. Polym. 15, 1203–1222 (2004).
   PubMed Web of Science ®Google Scholar